SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tktom12/7/2015 6:26:58 PM
   of 4474
 
And, finally Biomaven final conclusion on the new Ariad trial, which is stunningly accurate:

biomaven0 Monday, 12/07/15 03:23:42 PM
Re: DewDiligence post# 198035
Post # of 198052


The trial to my mind is simply dumb for multiple reasons. It's expensive and has no real upside - too short to show safety, and so will have little impact on actual sales even if it is "successful." More likely, results will be negative or mixed (because nilotinib performs very well in this population).

If they were doing this in the population I suggested, it would have a real chance of success - none of the other drugs work a damn in the population that have failed a second-line agent, while pona still works well, even at low dose. So any safety signals would very likely be offset by way better efficacy.

They never adjusted their mindset properly to pona's very real safety issues.

Peter

siliconinvestor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News